Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q2 FY21 results · Jul–Sep 2020
Natco Pharma reported revenue from operations of ₹802.20 crore (up 65.2% from Q2 FY20) and net profit of ₹203.90 crore (up 73.2% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 802.20 | 485.70 | +65.2% | 563.40 | +42.4% |
| Other income | 25.70 | 33.20 | −22.6% | 18.70 | +37.4% |
| Total income | 827.90 | 518.90 | +59.5% | 582.10 | +42.2% |
| Profit before tax | 270.70 | 139.40 | +94.2% | 158.10 | +71.2% |
| Net profit for the period | 203.90 | 117.70 | +73.2% | 122.10 | +67.0% |
| Attributable to shareholders of the company | 202.40 | 119.00 | +70.1% | 122.80 | +64.8% |
| EPS, basic (₹) | 11.12 | 6.55 | +69.8% | 6.74 | +65.0% |
| Net margin (%) | 25.4 | 24.2 | 21.7 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 478.90 | 457.70 | +4.6% | 532.20 | −10.0% |
| Other income | 27.20 | 33.90 | −19.8% | 19.90 | +36.7% |
| Total income | 506.10 | 491.60 | +2.9% | 552.10 | −8.3% |
| Profit before tax | 86.50 | 143.60 | −39.8% | 161.60 | −46.5% |
| Net profit for the period | 70.90 | 122.20 | −42.0% | 126.70 | −44.0% |
| EPS, basic (₹) | 3.89 | 6.72 | −42.1% | 6.96 | −44.1% |
| Net margin (%) | 14.8 | 26.7 | 23.8 |
Consolidated
- Filed with BSE
- 12 Nov 2020, 18:45 IST
- Board meeting
- 12 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2020, 18:45 IST
- Board meeting
- 12 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE